1. Decision-making on FP7 work programmes and calls
European Commission
Research and Inovation DG,
Directorate F Health
Grigorij Kogan
EKHA Meeting, Brussels 23/01/2012
23/02/2019

2. EU support for Research and Innovation
The €50 billion Seventh Framework Programme (FP7, ) supports basic and applied research activities, still far from the market, offers money and concentrates resources on strategic research areas, always on the basis of technological and scientific excellence.
The broad objectives of FP7 have been grouped into four categories:
Cooperation
Ideas
People
Capacities
For each type of objective, there is a specific programme corresponding to the main areas of EU research policy. All specific programmes work together to promote and encourage the creation of European poles of (scientific) excellence
23/02/2019

3. FP7 budget (2007-2013): €55 billion
= ~6% of public R&D investment in Europe
23/02/2019

4. Cooperation programme: thematic areas (€32.4 billion)
23/02/2019

5. http://bookshop. europa. eu/eubookshop/publicationDetails. action
23/02/2019

6. generic tools & technologies research for human health
FP7 Health Programme - structure
pillar 1:
Biotechnology,
generic tools & technologies
for health
pillar 2:
Translating
research for human health
pillar 3:
Optimising
the delivery
of health care
cross-cutting issues: child health, the health of ageing population gender-related health issues
Activity (Pillar) 4: Other actions across the theme
23/02/2019

7. Collaborative research in the Health theme
Main policy drivers:
Improving health of European citizens
Increasing competitiveness of European health-related industries and businesses
Addressing global health issues, including emerging epidemics
23/02/2019

8. across borders and other barriers
Collaborative research at European level
across borders and other barriers
between countries:
multinational consortia, with at least 3 partners from 27 EU Member States (MS) and / or Associated Countries (AC) e.g.: Albania, Croatia, FYR Macedonia, Iceland, Israel, Liechtenstein, Montenegro, Norway, Serbia, Switzerland, Turkey.
researchers from any country in the world can participate, from industrialised countries and from developing countries. e.g.: Argentina, Australia, Brazil, Canada, China, India, Japan, Korea, New-Zealand, Russia, South-Africa, USA…
between different types of organizations Public & private sector: universities, research centres, large companies, Small and medium-sized enterprises (SMEs), etc.
between disciplines: multidisciplinary, translational
23/02/2019

9. Collaborative research in the Health theme
1: Biotechnology, generic tools and technologies
High-throughput research
Detection, diagnosis and monitoring
Predicting suitability, safety and efficacy of therapies
Innovative therapeutic approaches and interventions
23/02/2019

10. Collaborative research in the Health theme
2: Translating research for human health
Integrating biological data and processes: large-scale data gathering, systems biology
Research on the brain and related diseases, human development and ageing
Translational research in major infectious diseases
Translational research in other major diseases
23/02/2019

11. Collaborative research in the Health theme
3: Optimising the delivery of healthcare
Translating clinical research into clinical practice
Quality, efficiency and solidarity of healthcare systems
Enhanced health promotion and disease prevention
23/02/2019

12. Collaborative research in the Health theme
4. Actions across the Theme
Coordination & Support Actions across the theme
Responding to EU policy needs
Specific International Cooperation Actions (SICAs)
23/02/2019

13. FP7 Cooperation Work Programme: Health-2012
23/02/2019
23/02/2019 13

14. Two-stage submission and evaluation procedure Timetable
Publication of call FP7-HEALTH-2012-INNOVATION-2
20 July 2011
Deadline for submission of stage 1 outline proposals
27 September 2011
Evaluation of stage 1 outline proposals
October 2011
ESRs sent to outline proposal coordinators (“initial information letters”, including invitation letters to successful applicants)
November 4, 2011
Deadline for submission of stage 2 full proposals
13 December 2011
Evaluation of stage 2 full proposals
January 2012
Ethical screening
By February 3, 2012
Invitation letter to successful coordinators to launch grant agreement negotiations with Commission services
By February , 2012
Negotiation kick-off meeting in Brussels
February 13, 2012
Signature of first grant agreements
April 2012
23/02/2019

15. Funding schemes in the Health theme
Funding schemes limits partners
Large-scale integrating project (CP-IP) ≥ €6m ≤ €12m ≥3
Network of Excellence (NoE) ≤ €12m ≥3
Small- or medium-scale focussed research project (CP-FP) ≤ €3m or €6m ≥3
Coordination action (CA)* ≤ €1.5m ≥3
Support action (SA)* ≤ €0.5m ≥1
* for CAs and SAs there are some exceptions.
23/02/2019

16. Policy dimensions: Industry (SME) participation & International Cooperation
Emphasis and special measures for:
Small & Medium-sized Enterprises (SMEs)
Opportunities and support measures
International Cooperation
the possibility to tackle issues on a global scale
an opportunity to extend networks beyond Europe
23/02/2019

17. Who prepares the work programmes for the Research Priorities
The EU Commission
Collects ideas for the preparation of the annual FP7 work program
Drafts the (annual) FP7 work plans
Within the EU Commission Scientific Officers (SO) are responsible for the preparatory work
Advisory Groups (AG)
Have been set up by the EU Commission for each of the FP7 themes
They provide consistent, consolidated advice for the work program
Members sit on the AG in their personal capacity and do not represent any organisation or country
National Contact Points (NCPs)
Are main providers of advice and individual assistance in all Member States and Associated States
Have been set up by the Member or Associated States so the type and level of services offered may differ from country to country
Programme Committees (PCs)
Play an important role at the end of the preparation process of each work program.
They have to give their approval for all the work programmes that have been prepared by he EU Commission.
Are involved quite early in the preparation process to insure that the preparation procedure works quick and smooth
23/02/2019

18. Scientific excellence at European level
From policy to funding the best research projects:
The policy for Health research is described in the FP7 specific programme (available on CORDIS
Each year, a work programme is prepared by the EC, in consultation with a scientific Advisory Group and with the Programme Committee
Through calls for proposals the EC invites researchers from all Europe and beyond to submit their proposals
The very best projects are selected on the basis of evaluation by independent experts (peer review)
After negotiation of a grant agreement, a project is funded for 2-5 years
23/02/2019

19. Submission & evaluation
Basic principles:
annual calls for proposals
eligibility (scope, partners, funding limits, deadline)
evaluation by panels of independent experts
overseen by Independent Observers
3 criteria:
Science & Technology excellence
Implementation & Management
Potential Impact
feedback: Evaluation Summary Reports (ESRs)
23/02/2019

20. Annual calls for proposals in the Health Theme
1st call (2007 budget): € 641 million
2nd call (2008 budget): € 577 million
3rd call (2009 budget): € 610 million
4th call (2010 budget): € 660 million
5th call (2011 budget): € 650 million
6th call (2012 budget): ~ € 645 million
7th call (2013 budget): ~
23/02/2019

21. The Innovative Medicines Initiative (IMI): the Largest PPP in Life Sciences R&D
Key Concepts Underlying IMI Projects:
Pre-competitive research
Open innovation
Why Public-Private Partnership?
Innovative medicines require in-depth knowledge of disease pathways and molecular targets
Anticipating potential side effects of new drugs is a must
The pharmaceutical industry builds new business models based on collaboration and transparency
Four Calls published since 2008:
23 projects funded
Over € 450 million committed
The Innovative medicines initiative clearly represents not only an innovative approach to supporting pharmaceutical research but will also result in the development of innovative medicines themselves.
15 projects were supported by the first call with an EFPIA in-kind contribution of 130 million, and an IMI JU (EC) contribution of 110 million. The figures for call 2 were 8, 68 and 80. The third call will see a 115 million EC contribution. 21
23/02/2019

22. Coverage of Kidney Diseases in FP7
Pillar IDEAS – ERC (European Research Council):
4 projects with € 6,813,200 EU Contribution
Pillar COOPERATION -
HEALTH: 7 projects with € 46,188,148 EU Contribution
INFSO: 2 projects with € 8,759,140 EU Contribution
Pillar PEOPLE – 13 projects with € 9,872,575 EU Contribution
Total EU Contribution - € 71,633,063
23/02/2019

23. 23/02/2019

24. Contacts & Information
FP7 Health web site:
NCPs:
Registration as an Expert:
FP7 calls:
Health projects database:
SMEsgoHealth:
23/02/2019

25. The Health Directorate
Director – Dr. Ruxandra Draghia-Akli:
Medical Research unit (F2)
Head of unit: Maria Vidal-Ragout
Deputy Head of Unit: Karim Berkouk
Infectious Diseases unit (F3)
Head of unit: Line Mathiessen
Deputy Head of unit: Anna Lönnroth
Avanced Therapies and Systems Medicine unit (F4)
Head of unit: Arnd Hoeveler
Deputy Head of unit: Bernard Mulligan
Personalized Medicine unit (F5)
Head of unit: Patrik Kolar
Deputy Head of unit: Irene Norstedt
Administration & Finance unit (F6) Head of unit: Georgios Zisimatos
Horizontal Aspects unit (F1) Head of unit: Stéphane Hogan
23/02/2019

26. What is Horizon 2020
23/02/2019

27. THANK YOU FOR YOUR ATTENTION!
Grigorij Kogan « Chronic Diseases »
Unit F-2 Medical Research
Directorate F « Health »
DG Research and Innovation
European Commission
23/02/2019